In the search for biomarkers in PsA, interesting study showing absolute lymphocyte count is negatively correlated with cardiovascular disease risk score and red cell distribution width and increases with TNF-Inhibitor Therapy @rheumnow #ACR20 Abstr#878

Dr. J. Walsh slide on PROs in PsA research. #ACR20 ⁦@RheumNow⁩ https://t.co/v4ufUdWufB

RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by Novartis. All content chosen by @RheumNow and its Faculty.

FUTURE2 analysis of 78 TJC and 76 SJC scores in PsA pts treated with SEC demonstrated improvements in synovitis at Week 24 sustained over 5 years, irrespective of TNFi history & concomitant MTX use. #ABS0875 #ACR20#ACRbest @RheumNow https://t.co/U8B50PTWET https://t.co/fUK1JO10ox

• Secukinumab Provides Sustained Improvements in Subgroup Analyses of Joint Tende…

CORRONA: Majority of PsA pts who initiated an advanced therapy had mild to moderate skin involvement. Decision to change therapy w/ rheumatologist based mainly on MSK symptoms. #ABS0873 #ACR20 @RheumNow https://t.co/mOXg5B7goI https://t.co/mqddMYQ3i0

• Impact of Skin Involvement on Disease Burden Among Patients with Psoriatic Arth…

Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis https://t.co/hgPDtFRxer #PsA #Guselkumab

• Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Result…

Think of Psoriatic Arthritis in the context of Psoriasis https://t.co/XpTFdzEHEa

• https://twitter.com/PsoriasisUK/status/1323951897288581122

Check out this session at 4 pm EST today on “Psoriatic Arthritis: Treatment in Practice” detailing emerging therapies and co-management strategies by this amazing team! #ACR20 @RheumNow https://t.co/baNtDLe6Rc

• https://twitter.com/elainehusnimd/status/1324805291263827973